Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.57 |
| ▸ | GRK5 | P34947 | 10/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | GRK2 | P25098 | 7/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16784460 | 0.91 | MET (0.69) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL16758571 | 0.90 | MET (0.69) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL16758529 | 0.90 | MET (0.56) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL16758539 | 0.90 | MET (0.55) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL16758567 | 0.90 | MET (0.54) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL22186607 | 0.89 | MET (0.54) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL16758559 | 0.88 | MAP3K7 (0.55) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL16758422 | 0.88 | MET (0.55) | METGRK5KCNH2MAP3K7TAB1 | |
| SCHEMBL22186608 | 0.87 | MET (0.62) | METGRK5KCNH2GRK2FLT3 | |
| SCHEMBL16758465 | 0.87 | MET (0.58) | METGRK5KCNH2GRK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299287-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-09-24 | — | — | US | claimed |
| EP-3074390-B1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2020-07-08 | — | — | EP | claimed |
| EP-3074390-A2 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SignalChem Lifesciences Corporation (CA) | 2016-10-05 | — | — | EP | claimed |
| WO-2015081257-A2 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2015-06-04 | — | — | WO | claimed |
| US-12097194-B2 | Combination therapy for treating blood cancer | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2024-09-24 | — | — | US | disclosed |
| EP-3852766-B1 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | SIGNALCHEM LIFESCIENCES CORP (CA) | 2024-05-08 | — | — | EP | disclosed |
| CN-112739349-B | Combination therapy for the treatment of hematological cancers | 圣诺康生命科学公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-110156770-B | Aminopyridine derivatives as inhibitors of TAM family kinases | 圣诺康生命科学公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20220031685-A1 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2022-02-03 | — | — | US | disclosed |
| US-11034685-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2021-06-15 | — | — | US | disclosed |
| US-11034686-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2021-06-15 | — | — | US | disclosed |
| CN-112739349-A | Combination therapy for the treatment of leukemia | 圣诺康生命科学公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10723725-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-07-28 | — | — | US | disclosed |
| EP-3074390-B1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2020-07-08 | — | — | EP | disclosed |
| CN-110156770-A | Aminopyrazole derivatives as TAM race kinase inhibitor | 圣诺康生命科学公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20190152965-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-05-23 | — | — | US | disclosed |
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2019-03-19 | — | — | US | disclosed |
| US-20170022189-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2017-01-26 | — | — | US | disclosed |
| EP-3074390-A2 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SignalChem Lifesciences Corporation (CA) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015081257-A2 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299287-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | MET 355/4885GRK5 185/4885KCNH2 2877/4885 |
| US-10723725-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | MET 355/4885GRK5 185/4885KCNH2 2877/4885 |
| US-11034685-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | MET 355/4885GRK5 185/4885KCNH2 2877/4885 |
| US-11034686-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | MET 355/4885GRK5 185/4885KCNH2 2877/4885 |
| US-20220031685-A1 | COMBINATION THERAPY FOR TREATING BLOOD CANCER | MCL1, BCL2, BCL3 | MET 71/4885GRK5 1015/4885KCNH2 4859/4885 |
| US-10233176-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | MET 355/4885GRK5 185/4885KCNH2 2877/4885 |
| US-12097194-B2 | Combination therapy for treating blood cancer | MCL1, BCL2, BCL3 | MET 71/4885GRK5 1015/4885KCNH2 4859/4885 |
| US-20170022189-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | MET 355/4885GRK5 185/4885KCNH2 2877/4885 |
| US-20190152965-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | MET 355/4885GRK5 185/4885KCNH2 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.